Tiger Gold Corp. announced assay results from three drill holes at its Ceibal target within the Quinchía Gold Project in Colombia. The drilling revealed significant gold mineralization, including intervals up to 465 meters grading 0.6 g/t gold and higher-grade zones reaching 2.9 g/t gold at depth. These results enhance understanding of the mineralized system and support plans for a maiden Mineral Resource estimate targeted for early 2027. Drilling continues to expand and define the deposit, with assays pending from additional holes.
Tiger Gold's recent drilling results provide context for readers interested in gold exploration. For readers following US stocks tradable on Pluang, here is the market snapshot as of Sep 15, 2026 15:51 WIB: out of 150 priced stocks, 25 rose and 119 fell. Among notable movers, Gold Fields Limited (GFI) traded at USD 42.29 with a 1-day change of -1.92%, contrasting with Nokia Corp (NOK) at USD 9.83 gaining 1.81%, while Freeport-McMoRan Inc (FCX) stood at USD 68.08, down 1.83%.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
In early November, Sui will unlock a tranche of tokens ranging from 2.07 million to 22.6 million SUI, representing up to 0.55% of the circulating supply. This unlock is part of a long-term vesting schedule with a 12-month cliff and 72 months of linea...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
